aFGF Targeted Mediated by Novel Nanoparticles-Microbubble Complex Combined With Ultrasound-Targeted Microbubble Destruction attenuates Doxorubicin-Induced Heart Failure via Anti-Apoptosis and Promoting Cardiac Angiogenesis.

Saved in:
Bibliographic Details
Title: aFGF Targeted Mediated by Novel Nanoparticles-Microbubble Complex Combined With Ultrasound-Targeted Microbubble Destruction attenuates Doxorubicin-Induced Heart Failure via Anti-Apoptosis and Promoting Cardiac Angiogenesis.
Authors: Zhou NQ; Department of Ultrasonography, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China.; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China., Fang ZX; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China.; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.; College of Pharmacy, Xinxiang Medical University, Xinxiang, China., Huang N; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China.; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.; College of Pharmacy, Xinxiang Medical University, Xinxiang, China., Zuo Y; School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China., Qiu Y; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China.; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.; College of Pharmacy, Xinxiang Medical University, Xinxiang, China., Guo LJ; Department of Oncology, First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China., Song P; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China.; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.; College of Pharmacy, Xinxiang Medical University, Xinxiang, China., Xu J; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China.; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.; College of Pharmacy, Xinxiang Medical University, Xinxiang, China., Wan GR; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China.; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.; College of Pharmacy, Xinxiang Medical University, Xinxiang, China., Tian XQ; Department of Ultrasonography, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China., Yin YL; School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China., Li P; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China.; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.; College of Pharmacy, Xinxiang Medical University, Xinxiang, China.
Source: Frontiers in pharmacology [Front Pharmacol] 2021 Apr 27; Vol. 12, pp. 607785. Date of Electronic Publication: 2021 Apr 27 (Print Publication: 2021).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1663-9812
DOI:10.3389/fphar.2021.607785